GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SunWay Biotech Co 1271.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

56.00

+0.18%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About SunWay Biotech Co

Its shares trade on Taipei Exchange under the ticker 1271.TWO. It has been listed since 18 January 2021. In the fiscal year to 31 December 2025, it reported revenue of TWD 993.3m and net income of TWD 101.5m. At that date it held total assets of TWD 4.46bn and shareholders' equity of TWD 3.26bn.

SunWay Biotech Co., Ltd. engages in the research, development, manufacture, and sale of red yeast health food. The company is headquartered in Taipei City, Taipei. The company went IPO on 2021-01-18. The firm's main products are involved in Lactobacillus paracasei subsp. paracasei NTU 101, Monascus purpureus NTU 568 and other related health foods. The firm's main product functions include helping digestion, improving the bacterial ecology of the digestive tract, regulating immunity and allergies. The firm operates products in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
18 Jan 2021
Website
sunway.cc ↗

Leadership

Pay as last reported

  • Mr. Pao-Hsi ShengChairman of the Board, since 2023
  • Jiayue PanVice Chairman of the Board, General Manager, since 2011
  • Bohan KeSenior Manager of Finance & Accounting Division, Corporate Governance Officer
  • Mr. Tzu-Ming PanChief Technology Officer
  • Jialing ChenDirector
  • Mr. Xuzhi XuDirector
  • Mr. Dun-Chien ChengIndependent Director
  • Mr. C.W. HsiehIndependent Director
  • Ms. Tsui-Ting KoIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • SunWay Biotech's Lactobacillus paracasei subsp. paracasei NTU 101 supports digestive health in Taiwan markets.
  • Monascus purpureus NTU 568 is a key product for immune regulation in the Health Care sector.
  • SunWay Biotech operates in both domestic and overseas markets for health food sales.

Weaknesses

  • SunWay Biotech's product range is limited to specific health foods like NTU 568.
  • The company's focus on red yeast health food may restrict market diversification.
  • SunWay Biotech's operations are primarily in Taipei City, limiting geographic reach.

Opportunities

  • Expanding Monascus purpureus NTU 568 into overseas markets for growth.
  • Increasing sales of Lactobacillus paracasei in domestic Taiwan health food segment.
  • Leveraging Health Care sector trends for new product development in Taiwan.

Threats

  • Competition from other Health Care companies in Taiwan's red yeast market.
  • Regulatory changes affecting pharmaceutical products in the Health Care sector.
  • Overreliance on specific products like NTU 568 for revenue generation.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.